Analysts Offer Predictions for CMPS FY2025 Earnings

COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for COMPASS Pathways in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings per share of ($2.05) for the year. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the firm posted ($0.67) EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright dropped their price objective on COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Maxim Group cut their price target on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways presently has an average rating of "Buy" and a consensus price target of $33.60.

COMPASS Pathways Stock Up 3.8 %

Shares of NASDAQ:CMPS traded up $0.14 on Wednesday, hitting $3.87. 1,729,540 shares of the company's stock were exchanged, compared to its average volume of 1,467,838. COMPASS Pathways has a 1-year low of $3.16 and a 1-year high of $12.75. The company has a market capitalization of $264.79 million, a PE ratio of -1.76 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm's 50-day moving average is $4.19 and its 200 day moving average is $5.80.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new position in COMPASS Pathways during the fourth quarter worth approximately $43,000. Green Alpha Advisors LLC purchased a new stake in shares of COMPASS Pathways during the 3rd quarter valued at $99,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of COMPASS Pathways during the 3rd quarter worth $131,000. Geode Capital Management LLC raised its position in shares of COMPASS Pathways by 160.3% in the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock worth $266,000 after buying an additional 25,970 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in COMPASS Pathways in the third quarter valued at $371,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.